The Critical Role of Clinical Pharmacology in Geriatric Psychopharmacology

Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
Clinical Pharmacology &#38 Therapeutics (Impact Factor: 7.39). 12/2008; 85(1):89-93. DOI: 10.1038/clpt.2008.229
Source: PubMed

ABSTRACT There is limited geriatrics-oriented clinical pharmacological information available to guide pharmacotherapy in late-life psychiatric disorders. In this paper, we review available data on interindividual differences in drug exposure and central nervous system functioning, amplified by drug-drug interactions in the elderly, that may contribute to variable responses to treatment and significant adverse drug effects. The inclusion of greater numbers of elderly persons in clinical trials and the vigorous application of clinical pharmacologic methodology (i.e., pharmacoepidemiology, population pharmacokinetic modeling, and pharmacogenetics) will be critical for improving safety and personalization of drug and dose selection for elderly patients.Clinical Pharmacology & Therapeutics (2008); 85, 1, 89-93 doi:10.1038/clpt.2008.229

Download full-text


Available from: Bruce G Pollock, Dec 20, 2013
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: agents administered during hospi- talization at a tertiary care acade- mic medical center. The retrospec- tive analysis was conducted over 1 year. A total of 416 allergies were reported among 300 patients; more than 1 allergy was reported by more than one-fourth of study patients (82/300 (27.3%)). Only 36.3% (151/416) of allergies reported were accompanied by a reaction description (95% confi- dence interval (CI), 31.7% to
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The purpose of the study was to investigate the risk of stroke with typical and atypical anti-psychotics in elderly subjects, weighting for a number of known risk factors, including dementia. Data were retrospectively drawn from the primary care setting from the Health Search Database, which stores information on about 1.5% of the total Italian population served by general practitioners. All elderly patients (65+ years) prescribed an anti-psychotic in monotherapy from January 2000 to June 2003 were selected for the study. A cohort of patients not exposed to anti-psychotics was taken from the same database. Subjects who had previously had a stroke were excluded. The main outcome measure was the incidence of first-ever stroke during exposure to an anti-psychotic.The sample included non-users (69,939), users of atypicals (599), butyrophenones (749), phenotiazines (907) and substituted benzamides (1,968). The crude incidence of stroke in subjects not exposed to anti-psychotics was 12.0/1000 person-years. Risk was significantly higher for those on butyrophenones (47.1/1000), phenotiazines (72.7/1000) and in the atypical anti-psychotic group (47.4/1000). Substituted benzamides had an almost significant higher risk (25.0/1000). Cox regression modelling, weighting for demographic and clinical variables with non-users as the reference group, showed that the risk for stroke was 5.79 times for phenotiazines, 3.55 times for butyrophenones, and 2.46 times for atypicals. Clinicians should be cautious in prescribing phenotiazines and butyrophenones in elderly patients, since the risk for stroke would seem comparable or even greater than with atypicals.
    Journal of Psychopharmacology 02/2008; 22(1):39-46. DOI:10.1177/0269881107080792 · 2.81 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Pharmacological treatment of dementia addresses two main clinical features of the disease: cognitive deterioration with predominantly memory loss and behavioural and psychological symptoms (BPSD). While cholinesterase inhibitors are recommended in an attempt to delay memory loss and disability, what should be considered the most appropriate pharmacological treatment for BPSD has remained questionable. Antipsychotic medications, conventional and atypical agents, have been increasingly utilized in clinical practice but only a small number of clinical studies have investigated their relative cost-benefit ratio. This review focuses on the safety of atypical and conventional antipsychotics when used in patients with BPSD. Overall, atypical and conventional antipsychotics are associated with a similarly increased risk for all-cause mortality and cerebrovascular events. Relative to atypical agents users, patients being treated with conventional antipsychotics have an increased incidence of cardiac arrhythmias and extrapyramidal symptoms. Conversely, users of atypical antipsychotics are exposed to an increased risk of venous thromboembolism and aspiration pneumonia. Also, metabolic effects (i.e. increased risk of diabetes, weight gain) have consistently been documented in clinical studies with atypical antipsychotics, although this effect tends to be attenuated with advancing age and in elderly patients with dementia. Antipsychotics, both conventional and atypical, should be used with caution only when nonpharmacologic approaches have failed to adequately control BPSD. More effective interventions are necessary to improve postmarket drug safety in vulnerable populations.
    Pharmacological Research 11/2008; 59(1):1-12. DOI:10.1016/j.phrs.2008.09.017 · 3.98 Impact Factor